Robatumumab

BIOLOGICAL4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Bone CancerColorectal CancerKidney TumorNeoplasmsNeuroblastomaOsteosarcomaPeripheral Neuroectodermal TumorSarcoma, Ewing's

Phase 1

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

TerminatedNCT00954512

Merck Sharp & Dohme LLCNeoplasms

Start: 2009-09-25End: 2011-06-07Updated: 2018-08-24

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

TerminatedNCT00960063

Merck Sharp & Dohme LLCBone Cancer, Kidney Tumor, Neoplasms +2

Start: 2009-11-11End: 2010-12-22Updated: 2018-08-27

Phase 2

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

CompletedNCT00551213

Merck Sharp & Dohme LLCColorectal Cancer

Start: 2007-11-21End: 2009-06-04Updated: 2018-08-24

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

TerminatedNCT00617890

Merck Sharp & Dohme LLCOsteosarcoma, Peripheral Neuroectodermal Tumor, Sarcoma, Ewing's

Start: 2008-02-01End: 2013-08-31Updated: 2018-08-23

Related Papers

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Pediatric Blood & Cancer2016-06-3096 citations